- Medicine, Molecular Virology & Epidemiology
- Director, Eugene B. Casey Hepatitis Research Center
- Baylor College of Medicine
- Houston, Texas, United States
- Fellowship at Baylor College Of Medicine Affiliate Hospitals
- NIH Special Fellow, Department of Virology & Epidemiology
- Advanced Training from Centers For Disease Control And Prevention
- Residency at University Of Kansas School of Medicine
- Residency at University Of Washington Hospital
- Residency at University Of California Hospitals & Clinics
- Graduate Certificate at University Of Kansas School Of Medicine
- MD from University Of Kansas
- Baylor College of Medicine
Honors & Awards
- Physician of the Year 2005
- Excellence Recognition Award, American Liver Foundation, South Texas Chapter
- Viral hepatitis and liver disease
- Blood-borne pathogens
Viral Hepatitis; Blood-Borne Pathogens; Molecular Determinants of HCV Treatment Failure; Small Animal Models for Viral Hepatitis Studies; Organoids for Viral Hepatitis Studies. The Eugene B. Casey Hepatitis Research Center and Diagnostic Laboratory (CRCDL) was established in 1988 as a facility whose program focuses on hepatitis and other blood-borne viruses, the diseases associated with these agents, their immunoprophylaxis and treatment.
Hepatitis C: State-of-the-art assays are being utilized to properly identify and characterize hepatitis C virus (HCV) in infected persons and to study its role in the immunopathogenesis of viral hepatitis. The safety and efficacy of new or novel treatment modalities are being investigated. Recent data strongly suggest that HCV persistence and/or resistance to treatment is a multifactorial process involving the host, the immune response, and the virus itself through its molecular interactions during the course of infection and treatment. We are interested in studying molecular determinants of viral sequences that could be associated with the chronicity of HCV infection and escape from treatment. To accomplish this goal, we plan to develop a small animal model for HCV infection based on humanized mouse liver which will be challenged with viral genomes collected from patients with different outcomes of infection including nonresponders to treatment. We will define which clusters of the genomic sequence are important for the outcome of the infection or treatment modality and characterize the molecular mechanisms involved in this process.
National Surveillance Study on Hemophilics: The CRCDL is involved in a national serosurveillance study sponsored by the Centers for Disease Control and Prevention for the purpose of identifying HAV, HBV, HCV, HPV B19 and other new emerging viral agents in the U.S. hemophilia population.
SEN-V Virus: SEN-V virus is a member of the TT virus superfamily. It has been shown to be transmitted to humans by blood with recovery occurring in a large percentage of patients. The risk of developing serious disease among chronically infected persons has not been established. We are examining transmission among transfused recipients who have developed non-A-E hepatitis using PCR technology and are comparing these results to blood recipients who did not develop hepatitis.
Dr. F. Blaine Hollinger has been actively involved in hepatitis research since joining the Department of Molecular Virology and Epidemiology at Baylor College of Medicine in Houston, Texas in 1968 and the Department of Medicine (GI/Baylor Liver Center) in 1981. He is currently Professor of Medicine, Molecular Virology & Epidemiology and Director of the Eugene B. Casey Hepatitis Research Center. He is a Fellow of the IDSA, the AGA, the ACG, and the AASLD. He received the Marquis Who's Who Lifetime Achievement Award and the American Men and Women of Science award and was a Rhodes Scholar designee for the Midwest Region. He has been an advisor and consultant on program projects, grants, and contracts related to viral hepatitis and drug therapy for the National Institutes of Health and the Food and Drug Administration (FDA) and a consultant to the Transfusion Transmitted Diseases Committee of the AABB. He served on the Blood Products Advisory Committee (BPAC) for the FDA becoming its Chairman in 1997 and again in 2010 for which he was presented with the Advisory Committee Service Award on each occasion.
Dr. Hollinger is an experienced researcher and hepatologist who has engaged in a number of national multicenter clinical trials and basic scientific projects related to viral hepatitis over the past 40 years. He has published over 275 articles, books and chapters in this field that includes the characterization and diagnosis of viral hepatitis agents, development of sensitive immunological assays, prophylaxis of hepatitis A and B, vaccine development, therapy of hepatitis B and C, studies on the immunopathogenesis and natural history of viral hepatitis, and the epidemiology of blood-borne pathogens and posttransfusion hepatitis. His current research interests are to determine how chronic HCV infection disrupts the insulin signaling pathway and interferes with the interferon response, to study the effect of HBx on viral replication that might lead to the development of a novel antiviral drug inhibitor and the prevention of hepatocellular carcinoma using human hepatocyte engrafted mice and human liver organoids to evaluate new therapeutic targets for HBV and HCV and to determine the role of occult hepatitis B in transfusion medicine. His clinic responsibilities include all aspects of acute and chronic liver disease.
- Troisi CL, Hollinger FB, Hoots WK, Contant C, Gill J, Ragni M, Parmley R, Sexauer C, Gomperts E, Buchanan G. "A multicenter study of viral hepatitis in a United States hemophilic population.." Blood. 1993 January 15;81(2):412-8. Pubmed PMID: 7678517
- Hollinger FB. "Controlling hepatitis B virus transmission in North America. The North American Regional Study Group.." Vaccine. 1990 March;8:S122-8; discuss. Pubmed PMID: 2139279
- Troisi CL, Hollinger FB. "Detection of antibodies to hepatitis C virus in seronegative patients using an immune complex dissociation assay.." J. Viral Hepat.. 1997;4(6):383-6. Pubmed PMID: 9430358
- Hollinger FB, Eickhoff T, Gershon A, Jong EC, Koff RS. "Discussion: who should receive hepatitis A vaccine? A strategy for controlling hepatitis A in the United States.." J. Infect. Dis.. 1995 March;171:S73-7. Pubmed PMID: 7876653
- Stramer SL, Hollinger FB, Katz LM, Kleinman S, Metzel PS, Gregory KR, Dodd RY. "Emerging infectious disease agents and their potential threat to transfusion safety.." Transfusion. 2009 August;49:1S-29S. Pubmed PMID: 19686562
- Hollinger FB. "Factors contributing to the evolution and outcome of cirrhosis in hepatitis C.." Clin Liver Dis. 1999 November;3(4):741-55, viii. Pubmed PMID: 11291248
- Hollinger FB. "Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations.." Am. J. Med.. 1989 September 4;87(3):36S-40S. Pubmed PMID: 2528297
- Hollinger FB, Bell B, Levy-Bruhl D, Shouval D, Wiersma S, Van Damme P. "Hepatitis A and B vaccination and public health.." J. Viral Hepat.. 2007 November;14:41279. Pubmed PMID: 17958635
- Hollinger FB. "Hepatitis B virus genetic diversity and its impact on diagnostic assays.." J. Viral Hepat.. 2007 November;14:41583. Pubmed PMID: 17958637
- Garcia G, Hollinger FB. "Hepatitis B virus infection and renal transplantation.." Hepatology. 8(5):1172-4. Pubmed PMID: 3047040
- Hollinger FB. "Hepatitis B virus infection and transfusion medicine: science and the occult.." Transfusion. 2008 May;48(5):1001-26. Pubmed PMID: 18454738
- Hollinger FB, Dodd RY. "Hepatitis B virus traceback and lookback: factors to consider.." Transfusion. 2009 January;49(1):176-84. Pubmed PMID: 19140810
- Hollinger FB, Lau DT. "Hepatitis B: the pathway to recovery through treatment.." Gastroenterol. Clin. North Am.. 2006 June;35(2):425-61, x. Pubmed PMID: 16880074
- Lerat H, Hollinger FB. "Hepatitis C virus (HCV) occult infection or occult HCV RNA detection?." J. Infect. Dis.. 2004 January 1;189(1):41339. Pubmed PMID: 14702146
- Troisi CL, Hollinger FB, Krause DS, Pickering LK. "Immunization of seronegative infants with hepatitis A vaccine (HAVRIX; SKB): a comparative study of two dosing schedules.." Vaccine. 1997 October;15(15):1613-7. Pubmed PMID: 9364691
- Keasler VV, Lerat H, Madden CR, Finegold MJ, McGarvey MJ, Mohammed EM, Forbes SJ, Lemon SM, Hadsell DL, Grona SJ, Hollinger FB, Slagle BL. "Increased liver pathology in hepatitis C virus transgenic mice expressing the hepatitis B virus X protein.." Virology. 2006 April 10;347(2):466-75. Pubmed PMID: 16427673
- Hollinger FB, Mouneimne Y, Lahart C, Tosi PF, Dimitrov D, Nicolau C. "Life span of circulating membrane CD4 inserted into the plasma membranes of autologous red blood cells of HIV-infected subjects.." J. Acquir. Immune Defic. Syndr. Hum. Retrovir. 1995 June 1;9(2):126-32. Pubmed PMID: 7749788
- Das GC, Hollinger FB. "Molecular pathways for glucose homeostasis, insulin signaling and autophagy in hepatitis C virus induced insulin resistance in a cellular model.." Virology. 2012 December 5;434(1):41411. Pubmed PMID: 22862962
- Stramer SL, Wend U, Candotti D, Foster GA, Hollinger FB, Dodd RY, Allain JP, Gerlich W. "Nucleic acid testing to detect HBV infection in blood donors.." N. Engl. J. Med.. 2011 January 20;364(3):236-47. Pubmed PMID: 21247314
- Hollinger FB, Sood G. "Occult hepatitis B virus infection: a covert operation.." J. Viral Hepat.. 2010 January;17(1):41289. Pubmed PMID: 20002296
- Lin HJ, Seeff LB, Barbosa L, Hollinger FB. "Occurrence of identical hypervariable region 1 sequences of hepatitis C virus in transfusion recipients and their respective blood donors: divergence over time.." Hepatology. 2001 August;34(2):424-9. Pubmed PMID: 11481629
- Han KH, Hollinger FB, Noonan CA, Solomon H, Klintmalm GB, Genta RM, Yoffe B. "Southern-blot analysis and simultaneous in situ detection of hepatitis B virus-associated DNA and antigens in patients with end-stage liver disease.." Hepatology. 1993 November;18(5):1032-8. Pubmed PMID: 8225208
- Hollinger FB, Bremer JW, Myers LE, Gold JW, McQuay L. "Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. The NIH/NIAID/DAIDS/ACTG Virology Laboratories.." J. Clin. Microbiol.. 1992 July;30(7):1787-94. Pubmed PMID: 1629336
- Lin HJ, Lau JY, Lauder IJ, Shi N, Lai CL, Hollinger FB. "The hepatitis C virus genome: a guide to its conserved sequences and candidate epitopes.." Virus Res.. 1993 October;30(1):27-41. Pubmed PMID: 7505514
- Hollinger FB, Kleinman S. "Transfusion transmission of West Nile virus: a merging of historical and contemporary perspectives.." Transfusion. 2003 August;43(8):992-7. Pubmed PMID: 12869102
- Kline MW, Lewis DE, Hollinger FB, Reuben JM, Hanson LC, Kozinetz CA, Dimitrov DH, Rosenblatt HM, Shearer WT. "A comparative study of human immunodeficiency virus culture, polymerase chain reaction and anti-human immunodeficiency virus immunoglobulin A antibody detection in the diagnosis during early infancy of vertically acquired human immunodeficiency virus infe." Pediatr. Infect. Dis. J.. 1994 February;13(2):90-4. Pubmed PMID: 8190557
- Hollinger FB. "Comprehensive control (or elimination) of hepatitis B virus transmission in the United States.." Gut. 1996;38:S24-30. Pubmed PMID: 8786049
- "A COLLECTION OF ARTICLES, CHAPTERS FROM >275 PUBLICATIONS."
- Hollinger FB, Martin A. "Hepatitis A Virus." Fields Virology. 2013;6th Edition(Chapter 19):550-581.
- Hollinger FB, Liang TJ. "Hepatitis B Virus." Fields Virology. 2001;4th Edition(Chapter 87):2971-3036.
- Eugene B. Casey Foundation
- Baylor College of Medicine